- XORTX Therapeutics (XRX) has been granted a European patent for the prevention and treatment of diabetic nephropathy
- The patent covers compositions and methods to prevent and treat diabetic nephropathy using a uric acid-lowering agent and xanthine oxidase inhibitors
- The patent will help XORTX expand clinical trials, commercialization and partnering opportunities worldwide
- XORTX is focused on developing therapeutics for chronic progressing kidney disease, hypertension, insulin resistance and diabetic nephropathy
- XORTX Therapeutics (XRX) is up by 17.78 per cent and is currently trading at $0.53 per share
XORTX Therapeutics (XRX) has been granted a European patent for the prevention and treatment of diabetic nephropathy.
The patent is entitled, “EPO National Stage of PCT International Application for Compositions and Methods for Treatment and Prevention of Hyperuricemia Related Health Consequences”.
The patent covers compositions and methods to prevent and treat diabetic nephropathy using a uric acid-lowering agent and xanthine oxidase inhibitors.
Aberrant purine metabolism and chronically increased serum uric acid concentrations are associated with kidney disease progression.
The company’s XRx-225 is a small molecule drug development program focused on treating and preventing chronic kidney disease due to diabetes through xanthine oxidase inhibition.
According to the CDC, more than 37 million U.S. adults have chronic kidney disease, and of those, diabetic nephropathy contributes to half of all individuals.
Dr. Allen Davidoff, XORTX’s CEO, stated,
“This newly granted patent provides XORTX with protection to key markets within the European region. This issuance strengthens our intellectual property portfolio in the EU and globally. Grant of this patent provides the protection to expand our clinical trials, commercialization and partnering opportunities worldwide. With this newly allowed patent, XORTX now has multiple granted patents in the U.S. and/or EU covering compositions and uses of uric acid-lowering agents and/or xanthine oxidase inhibitors to treat and prevent chronic progressing kidney disease, hypertension, insulin resistance and diabetic nephropathy.”
XORTX is focused on developing therapeutics for chronic progressing kidney disease, hypertension, insulin resistance and diabetic nephropathy.
XORTX Therapeutics (XRX) is up by 17.78 per cent and is currently trading at $0.53 per share as of 11:09 am ET.